ZHU Qing
Principal Investigator
After having completed his medical education and residency, Zhu Qing obtained a Ph.D. degree from McMaster University and then moved to Bethesda for a postdoctoral fellowship and later took a research fellow position at National Institutes of Health. He came to the Institute of Materia Medica as Principal Investigator in the Department of Pharmacology, focusing his research primarily on the cellular immune responses to vaccines and aiming to elucidate the cellular and molecular mechanisms involved in T cell immunity particularly at the mucosal surfaces against infectious and inflammatory diseases as well as cancer. He also conducts research into the therapeutic potential of cellular reprogramming in disease models and is pursuing interdisciplinary studies at the interface of basic and applied science to understand how cells could be manipulated to treat the diseases that are still incurable.
1. Micro- and nanoencapsulated hybrid delivery system (MNEHDS): a novel approach for colon-targeted oral delivery of Berberine. Mol Pharm . 2021. 18(4):1573-1581.
2. Oral immunization induces a novel CXCR6(+) beta7(+) intraepithelial lymphocyte subset predominating in the small intestine. Scand J Immunol . 2021. 93(3):e12996.
3. Fingolimod can act as a facilitator to establish the primary T-cell response with reduced need of adjuvants. Vaccine . 2018. 36(50):7632–7640.
4. Regenerative approaches for cartilage repair in the treatment of osteoarthritis. Osteoarthritis Cartilage . 2017. 25(10):1577-1587.
5. Oral vaccines: directed safe passage to the front line of defense. Gut Microbes . 2013. 4(3):246-252.
6. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med . 2012. 18(8):1291-1296.
7. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest . 2010. 120(2):607-616.
